Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men—United States, 2016–2018
Abstract Background In the United States, human papillomavirus (HPV) vaccination has been recommended for young adult men who have sex with men (MSM) since 2011. Methods The Vaccine Impact in Men study surveyed MSM and transgender women aged 18–26 years in 3 US cities during 2016–2018. Self-collecte...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2020-12, Vol.222 (12), p.2052-2060 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2060 |
|---|---|
| container_issue | 12 |
| container_start_page | 2052 |
| container_title | The Journal of infectious diseases |
| container_volume | 222 |
| creator | Meites, Elissa Winer, Rachel L Newcomb, Michael E Gorbach, Pamina M Querec, Troy D Rudd, Jessica Collins, Tom Lin, John Moore, Janell Remble, Thomas Swanson, Fred Franz, Justin Bolan, Robert K Golden, Matthew R Mustanski, Brian Crosby, Richard A Unger, Elizabeth R Markowitz, Lauri E |
| description | Abstract
Background
In the United States, human papillomavirus (HPV) vaccination has been recommended for young adult men who have sex with men (MSM) since 2011.
Methods
The Vaccine Impact in Men study surveyed MSM and transgender women aged 18–26 years in 3 US cities during 2016–2018. Self-collected anal swab and oral rinse specimens were assessed for 37 types of HPV. We compared HPV prevalence among vaccinated and unvaccinated participants and determined adjusted prevalence ratios (aPR) and 95% confidence intervals (CI).
Results
Among 1767 participants, 704 (39.8%) self-reported receiving HPV vaccine. Median age at vaccination (18.7 years) was older than age at first sex (15.7 years). Quadrivalent vaccine-type HPV was detected in anal or oral specimens from 475 (26.9%) participants. Vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants; aPR for those who initiated vaccination at age ≤18 years was 0.41 (CI, 0.24–0.57) and at age >18 years was 0.82 (CI, 0.67–0.98). Vaccine effectiveness of at least 1 HPV vaccine dose at age ≤18 years or >18 years was 59% and 18%, respectively.
Conclusions
Findings suggest real-world effectiveness of HPV vaccination among young adult MSM. This effect was stronger with younger age at vaccination.
Among 1767 men who have sex with men and transgender women aged 18–26 years in US cities during 2016–2018, vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants, suggesting real-world effectiveness of HPV vaccination. |
| doi_str_mv | 10.1093/infdis/jiaa306 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7669535</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/infdis/jiaa306</oup_id><sourcerecordid>2476870662</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-6b7ab72715cde13bedb2890a0aa36b55316c0d227c98073ba687ae00cb66ae753</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EokNhyxJZYgMSaf0zsScbpFFVmEpFrVRKl9aNczPjUWIPcRLBrq-A4An7JHiYoQI2rK5lfz665xxCnnN2xFkhj52vKxeP1w5AMvWATHgudaYUlw_JhDEhMj4rigPyJMY1Y2wqlX5MDqTI2ZQVfEK-fQJrnUd6WtdoezeixxjpfAnOx55edjhCg76ncw8NBV_Riy4dFkMLnl7CxjVNaGF03RDpmf8lETydt8Ev6Qf09GYV6AJGpFf4hd64frW9vbv9ce1djxW96qHH-IYKxtXd7fc0Zk_JoxqaiM_285Bcvzv9eLLIzi_en53MzzM7zUWfqVJDqYXmua2QyxKrUswKBiwFoco8l1xZVgmhbTFjWpagZhqQMVsqBahzeUje7nQ3Q9liZZPJ5MxsOtdC99UEcObvF-9WZhlGo5UqcrkVeLUX6MLnAWNvWhctNg14DEM0YspZijvlnNCX_6DrMHQp0S2l02ZMKZGoox1luxBjh_X9MpyZbdtm17bZt50-vPjTwj3-u94EvN4BYdj8T-wnXa64Vg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2476870662</pqid></control><display><type>article</type><title>Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men—United States, 2016–2018</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Meites, Elissa ; Winer, Rachel L ; Newcomb, Michael E ; Gorbach, Pamina M ; Querec, Troy D ; Rudd, Jessica ; Collins, Tom ; Lin, John ; Moore, Janell ; Remble, Thomas ; Swanson, Fred ; Franz, Justin ; Bolan, Robert K ; Golden, Matthew R ; Mustanski, Brian ; Crosby, Richard A ; Unger, Elizabeth R ; Markowitz, Lauri E</creator><creatorcontrib>Meites, Elissa ; Winer, Rachel L ; Newcomb, Michael E ; Gorbach, Pamina M ; Querec, Troy D ; Rudd, Jessica ; Collins, Tom ; Lin, John ; Moore, Janell ; Remble, Thomas ; Swanson, Fred ; Franz, Justin ; Bolan, Robert K ; Golden, Matthew R ; Mustanski, Brian ; Crosby, Richard A ; Unger, Elizabeth R ; Markowitz, Lauri E</creatorcontrib><description>Abstract
Background
In the United States, human papillomavirus (HPV) vaccination has been recommended for young adult men who have sex with men (MSM) since 2011.
Methods
The Vaccine Impact in Men study surveyed MSM and transgender women aged 18–26 years in 3 US cities during 2016–2018. Self-collected anal swab and oral rinse specimens were assessed for 37 types of HPV. We compared HPV prevalence among vaccinated and unvaccinated participants and determined adjusted prevalence ratios (aPR) and 95% confidence intervals (CI).
Results
Among 1767 participants, 704 (39.8%) self-reported receiving HPV vaccine. Median age at vaccination (18.7 years) was older than age at first sex (15.7 years). Quadrivalent vaccine-type HPV was detected in anal or oral specimens from 475 (26.9%) participants. Vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants; aPR for those who initiated vaccination at age ≤18 years was 0.41 (CI, 0.24–0.57) and at age >18 years was 0.82 (CI, 0.67–0.98). Vaccine effectiveness of at least 1 HPV vaccine dose at age ≤18 years or >18 years was 59% and 18%, respectively.
Conclusions
Findings suggest real-world effectiveness of HPV vaccination among young adult MSM. This effect was stronger with younger age at vaccination.
Among 1767 men who have sex with men and transgender women aged 18–26 years in US cities during 2016–2018, vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants, suggesting real-world effectiveness of HPV vaccination.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jiaa306</identifier><identifier>PMID: 32504091</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject><![CDATA[Adolescent ; Adult ; Age ; Alphapapillomavirus ; Anus Diseases - prevention & control ; Anus Diseases - virology ; Cross-Sectional Studies ; Female ; Gays & lesbians ; Human papillomavirus ; Humans ; Immunization ; Major and Brief Reports ; Male ; Mens health ; Mouth Diseases - prevention & control ; Mouth Diseases - virology ; Papillomavirus Infections - prevention & control ; Papillomavirus Vaccines - administration & dosage ; Prevalence ; Self Report ; Sexual and Gender Minorities ; Transgender Persons ; Treatment Outcome ; United States ; Vaccination ; Vaccination - statistics & numerical data ; Vaccine efficacy ; Vaccines ; Young Adult ; Young adults]]></subject><ispartof>The Journal of infectious diseases, 2020-12, Vol.222 (12), p.2052-2060</ispartof><rights>Published by Oxford University Press for the Infectious Diseases Society of America 2020. 2020</rights><rights>Published by Oxford University Press for the Infectious Diseases Society of America 2020.</rights><rights>Published by Oxford University Press for the Infectious Diseases Society of America 2020. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-6b7ab72715cde13bedb2890a0aa36b55316c0d227c98073ba687ae00cb66ae753</citedby><cites>FETCH-LOGICAL-c452t-6b7ab72715cde13bedb2890a0aa36b55316c0d227c98073ba687ae00cb66ae753</cites><orcidid>0000-0002-0077-2591</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32504091$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meites, Elissa</creatorcontrib><creatorcontrib>Winer, Rachel L</creatorcontrib><creatorcontrib>Newcomb, Michael E</creatorcontrib><creatorcontrib>Gorbach, Pamina M</creatorcontrib><creatorcontrib>Querec, Troy D</creatorcontrib><creatorcontrib>Rudd, Jessica</creatorcontrib><creatorcontrib>Collins, Tom</creatorcontrib><creatorcontrib>Lin, John</creatorcontrib><creatorcontrib>Moore, Janell</creatorcontrib><creatorcontrib>Remble, Thomas</creatorcontrib><creatorcontrib>Swanson, Fred</creatorcontrib><creatorcontrib>Franz, Justin</creatorcontrib><creatorcontrib>Bolan, Robert K</creatorcontrib><creatorcontrib>Golden, Matthew R</creatorcontrib><creatorcontrib>Mustanski, Brian</creatorcontrib><creatorcontrib>Crosby, Richard A</creatorcontrib><creatorcontrib>Unger, Elizabeth R</creatorcontrib><creatorcontrib>Markowitz, Lauri E</creatorcontrib><title>Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men—United States, 2016–2018</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Abstract
Background
In the United States, human papillomavirus (HPV) vaccination has been recommended for young adult men who have sex with men (MSM) since 2011.
Methods
The Vaccine Impact in Men study surveyed MSM and transgender women aged 18–26 years in 3 US cities during 2016–2018. Self-collected anal swab and oral rinse specimens were assessed for 37 types of HPV. We compared HPV prevalence among vaccinated and unvaccinated participants and determined adjusted prevalence ratios (aPR) and 95% confidence intervals (CI).
Results
Among 1767 participants, 704 (39.8%) self-reported receiving HPV vaccine. Median age at vaccination (18.7 years) was older than age at first sex (15.7 years). Quadrivalent vaccine-type HPV was detected in anal or oral specimens from 475 (26.9%) participants. Vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants; aPR for those who initiated vaccination at age ≤18 years was 0.41 (CI, 0.24–0.57) and at age >18 years was 0.82 (CI, 0.67–0.98). Vaccine effectiveness of at least 1 HPV vaccine dose at age ≤18 years or >18 years was 59% and 18%, respectively.
Conclusions
Findings suggest real-world effectiveness of HPV vaccination among young adult MSM. This effect was stronger with younger age at vaccination.
Among 1767 men who have sex with men and transgender women aged 18–26 years in US cities during 2016–2018, vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants, suggesting real-world effectiveness of HPV vaccination.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Alphapapillomavirus</subject><subject>Anus Diseases - prevention & control</subject><subject>Anus Diseases - virology</subject><subject>Cross-Sectional Studies</subject><subject>Female</subject><subject>Gays & lesbians</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Immunization</subject><subject>Major and Brief Reports</subject><subject>Male</subject><subject>Mens health</subject><subject>Mouth Diseases - prevention & control</subject><subject>Mouth Diseases - virology</subject><subject>Papillomavirus Infections - prevention & control</subject><subject>Papillomavirus Vaccines - administration & dosage</subject><subject>Prevalence</subject><subject>Self Report</subject><subject>Sexual and Gender Minorities</subject><subject>Transgender Persons</subject><subject>Treatment Outcome</subject><subject>United States</subject><subject>Vaccination</subject><subject>Vaccination - statistics & numerical data</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Young Adult</subject><subject>Young adults</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAUhS0EokNhyxJZYgMSaf0zsScbpFFVmEpFrVRKl9aNczPjUWIPcRLBrq-A4An7JHiYoQI2rK5lfz665xxCnnN2xFkhj52vKxeP1w5AMvWATHgudaYUlw_JhDEhMj4rigPyJMY1Y2wqlX5MDqTI2ZQVfEK-fQJrnUd6WtdoezeixxjpfAnOx55edjhCg76ncw8NBV_Riy4dFkMLnl7CxjVNaGF03RDpmf8lETydt8Ev6Qf09GYV6AJGpFf4hd64frW9vbv9ce1djxW96qHH-IYKxtXd7fc0Zk_JoxqaiM_285Bcvzv9eLLIzi_en53MzzM7zUWfqVJDqYXmua2QyxKrUswKBiwFoco8l1xZVgmhbTFjWpagZhqQMVsqBahzeUje7nQ3Q9liZZPJ5MxsOtdC99UEcObvF-9WZhlGo5UqcrkVeLUX6MLnAWNvWhctNg14DEM0YspZijvlnNCX_6DrMHQp0S2l02ZMKZGoox1luxBjh_X9MpyZbdtm17bZt50-vPjTwj3-u94EvN4BYdj8T-wnXa64Vg</recordid><startdate>20201215</startdate><enddate>20201215</enddate><creator>Meites, Elissa</creator><creator>Winer, Rachel L</creator><creator>Newcomb, Michael E</creator><creator>Gorbach, Pamina M</creator><creator>Querec, Troy D</creator><creator>Rudd, Jessica</creator><creator>Collins, Tom</creator><creator>Lin, John</creator><creator>Moore, Janell</creator><creator>Remble, Thomas</creator><creator>Swanson, Fred</creator><creator>Franz, Justin</creator><creator>Bolan, Robert K</creator><creator>Golden, Matthew R</creator><creator>Mustanski, Brian</creator><creator>Crosby, Richard A</creator><creator>Unger, Elizabeth R</creator><creator>Markowitz, Lauri E</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0077-2591</orcidid></search><sort><creationdate>20201215</creationdate><title>Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men—United States, 2016–2018</title><author>Meites, Elissa ; Winer, Rachel L ; Newcomb, Michael E ; Gorbach, Pamina M ; Querec, Troy D ; Rudd, Jessica ; Collins, Tom ; Lin, John ; Moore, Janell ; Remble, Thomas ; Swanson, Fred ; Franz, Justin ; Bolan, Robert K ; Golden, Matthew R ; Mustanski, Brian ; Crosby, Richard A ; Unger, Elizabeth R ; Markowitz, Lauri E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-6b7ab72715cde13bedb2890a0aa36b55316c0d227c98073ba687ae00cb66ae753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Alphapapillomavirus</topic><topic>Anus Diseases - prevention & control</topic><topic>Anus Diseases - virology</topic><topic>Cross-Sectional Studies</topic><topic>Female</topic><topic>Gays & lesbians</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Immunization</topic><topic>Major and Brief Reports</topic><topic>Male</topic><topic>Mens health</topic><topic>Mouth Diseases - prevention & control</topic><topic>Mouth Diseases - virology</topic><topic>Papillomavirus Infections - prevention & control</topic><topic>Papillomavirus Vaccines - administration & dosage</topic><topic>Prevalence</topic><topic>Self Report</topic><topic>Sexual and Gender Minorities</topic><topic>Transgender Persons</topic><topic>Treatment Outcome</topic><topic>United States</topic><topic>Vaccination</topic><topic>Vaccination - statistics & numerical data</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Young Adult</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meites, Elissa</creatorcontrib><creatorcontrib>Winer, Rachel L</creatorcontrib><creatorcontrib>Newcomb, Michael E</creatorcontrib><creatorcontrib>Gorbach, Pamina M</creatorcontrib><creatorcontrib>Querec, Troy D</creatorcontrib><creatorcontrib>Rudd, Jessica</creatorcontrib><creatorcontrib>Collins, Tom</creatorcontrib><creatorcontrib>Lin, John</creatorcontrib><creatorcontrib>Moore, Janell</creatorcontrib><creatorcontrib>Remble, Thomas</creatorcontrib><creatorcontrib>Swanson, Fred</creatorcontrib><creatorcontrib>Franz, Justin</creatorcontrib><creatorcontrib>Bolan, Robert K</creatorcontrib><creatorcontrib>Golden, Matthew R</creatorcontrib><creatorcontrib>Mustanski, Brian</creatorcontrib><creatorcontrib>Crosby, Richard A</creatorcontrib><creatorcontrib>Unger, Elizabeth R</creatorcontrib><creatorcontrib>Markowitz, Lauri E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meites, Elissa</au><au>Winer, Rachel L</au><au>Newcomb, Michael E</au><au>Gorbach, Pamina M</au><au>Querec, Troy D</au><au>Rudd, Jessica</au><au>Collins, Tom</au><au>Lin, John</au><au>Moore, Janell</au><au>Remble, Thomas</au><au>Swanson, Fred</au><au>Franz, Justin</au><au>Bolan, Robert K</au><au>Golden, Matthew R</au><au>Mustanski, Brian</au><au>Crosby, Richard A</au><au>Unger, Elizabeth R</au><au>Markowitz, Lauri E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men—United States, 2016–2018</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2020-12-15</date><risdate>2020</risdate><volume>222</volume><issue>12</issue><spage>2052</spage><epage>2060</epage><pages>2052-2060</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Abstract
Background
In the United States, human papillomavirus (HPV) vaccination has been recommended for young adult men who have sex with men (MSM) since 2011.
Methods
The Vaccine Impact in Men study surveyed MSM and transgender women aged 18–26 years in 3 US cities during 2016–2018. Self-collected anal swab and oral rinse specimens were assessed for 37 types of HPV. We compared HPV prevalence among vaccinated and unvaccinated participants and determined adjusted prevalence ratios (aPR) and 95% confidence intervals (CI).
Results
Among 1767 participants, 704 (39.8%) self-reported receiving HPV vaccine. Median age at vaccination (18.7 years) was older than age at first sex (15.7 years). Quadrivalent vaccine-type HPV was detected in anal or oral specimens from 475 (26.9%) participants. Vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants; aPR for those who initiated vaccination at age ≤18 years was 0.41 (CI, 0.24–0.57) and at age >18 years was 0.82 (CI, 0.67–0.98). Vaccine effectiveness of at least 1 HPV vaccine dose at age ≤18 years or >18 years was 59% and 18%, respectively.
Conclusions
Findings suggest real-world effectiveness of HPV vaccination among young adult MSM. This effect was stronger with younger age at vaccination.
Among 1767 men who have sex with men and transgender women aged 18–26 years in US cities during 2016–2018, vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants, suggesting real-world effectiveness of HPV vaccination.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>32504091</pmid><doi>10.1093/infdis/jiaa306</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-0077-2591</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2020-12, Vol.222 (12), p.2052-2060 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7669535 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Age Alphapapillomavirus Anus Diseases - prevention & control Anus Diseases - virology Cross-Sectional Studies Female Gays & lesbians Human papillomavirus Humans Immunization Major and Brief Reports Male Mens health Mouth Diseases - prevention & control Mouth Diseases - virology Papillomavirus Infections - prevention & control Papillomavirus Vaccines - administration & dosage Prevalence Self Report Sexual and Gender Minorities Transgender Persons Treatment Outcome United States Vaccination Vaccination - statistics & numerical data Vaccine efficacy Vaccines Young Adult Young adults |
| title | Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men—United States, 2016–2018 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T15%3A00%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccine%20Effectiveness%20Against%20Prevalent%20Anal%20and%20Oral%20Human%20Papillomavirus%20Infection%20Among%20Men%20Who%20Have%20Sex%20With%20Men%E2%80%94United%20States,%202016%E2%80%932018&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Meites,%20Elissa&rft.date=2020-12-15&rft.volume=222&rft.issue=12&rft.spage=2052&rft.epage=2060&rft.pages=2052-2060&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jiaa306&rft_dat=%3Cproquest_pubme%3E2476870662%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2476870662&rft_id=info:pmid/32504091&rft_oup_id=10.1093/infdis/jiaa306&rfr_iscdi=true |